University of Cincinnati, Arch Biopartners deal

The university granted Arch a one-year option to license exclusive commercial rights to a pending U.S. patent covering a candidate to treat Pseudomonas aeruginosa respiratory infections. Arch plans to start a clinical trial this year to test the product in cystic fibrosis (CF) patients. The partners did not respond to inquiries. ...